Investigation of interleukin 18 polymorphism in hepatit B virus carriers chronic hepatitis and cirrhosis patients
Yazarlar (3)
| Makale Türü | Özgün Makale (Diğer hakemli uluslarası dergilerde yayınlanan tam makale) | ||
| Dergi Adı | Journal of Experimental and Integrative Medicine | ||
| Dergi ISSN | 1309-4572 Scopus Dergi | ||
| Dergi Tarandığı Indeksler | EBSCO, DOAJ, ScopeMed, Index Scholar, Akademik Dizin | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2014 |
| Cilt / Sayı / Sayfa | 4 / 3 / 175– | DOI | 10.5455/jeim.150514.or.105 |
| Makale Linki | http://www.scopemed.org/?mno=158328 | ||
| Özet |
| Hepatitis B virus (HBV) infection is a majority problem of public health in the world. An estimated 350-400 million people worldwide are chronically infected with HBV [1, 2]. Wang et al.[3] have reported approximately 250,000 deaths to happen each year as a consequence of hepatic failure, cirrhosis and hepatocellular carcinoma.The cytokine-mediated immunity plays a crucial role in determining of hepatitis infections overcome. The variations in cytokine production may influence the outcome of cytokinebased immunotherapy [4, 5]. Cytokine gene polymorphisms were associated with the severity of the liver disease in patients with HBV infection [6]. Interleukin (IL)-18 is a pleiotropic proinflammatory cytokine. It is a member of the IL-1 family and was first identified as interferon-gamma inducing factor [7-9]. IL-18 is synthesized as a 24-kDa proform which is activated to |
| Anahtar Kelimeler |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 3 |